News

centerforbiosimilars1d
Joseph P. Fuhr, PhD
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars1d
Gary Fanjiang, MD, MBA, MS
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
Center for Biosimilars2d
Yesintek Biosimilar Shows Comparable Efficacy, Lower Immunogenicity Than Stelara, Says Elena Wolff-Holz, MD
Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to ...
centerforbiosimilars2d
Camlyn Masuda, PharmD, BCACP, CDCES
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars3d
Soni Gupta, MEc
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars3d
Juliana M. Reed
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars3d
Christopher M. Bruno, JD
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars3d
Hillel P. Cohen, PhD
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars3d
Anna Chen, PharmD, MS
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars3d
Bincy P. Abraham, MD
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
Center for Biosimilars4d
The Top 5 Biosimilar Articles for the Week of May 5
Number 5: The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed ...